Oppenheimer Holdings, Inc. restated their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report issued on Monday morning.

Other equities analysts have also recently issued reports about the company. Vetr cut Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $31.05 price objective on the stock. in a report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research report on Thursday, June 22nd. BidaskClub lowered Teva Pharmaceutical Industries Limited from a sell rating to a strong sell rating in a research report on Wednesday, August 16th. Jefferies Group LLC reduced their price target on Teva Pharmaceutical Industries Limited from $21.00 to $18.50 and set a hold rating on the stock in a research report on Tuesday. Finally, Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and reduced their price target for the stock from $32.00 to $19.00 in a research report on Wednesday, August 16th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $32.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 4.459% during mid-day trading on Monday, hitting $19.325. The stock had a trading volume of 50,688,017 shares. The company’s 50 day moving average price is $20.66 and its 200 day moving average price is $29.02. The firm’s market cap is $19.63 billion. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 earnings per share. Analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/12/teva-pharmaceutical-industries-limited-teva-receives-hold-rating-from-oppenheimer-holdings-inc.html.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.84%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

A number of large investors have recently made changes to their positions in TEVA. Capital Research Global Investors raised its stake in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. raised its stake in Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the last quarter. FMR LLC raised its stake in Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the last quarter. Capital World Investors raised its stake in Teva Pharmaceutical Industries Limited by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after buying an additional 2,782,257 shares during the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.